Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Mantel-Cox Log-Rank Test01:19

The Mantel-Cox Log-Rank Test

The Mantel-Cox log-rank test is a widely used statistical method for comparing the survival distributions of two groups. It tests whether a statistically significant difference exists in survival times between the groups without assuming a specific distribution for the survival data, making it a non-parametric test. This flexibility makes the log-rank test particularly valuable in medical research and other fields where the timing of an event, such as death or disease recurrence, is of interest.
Assumptions of Survival Analysis01:15

Assumptions of Survival Analysis

Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
Data Validation01:03

Data Validation

Data validation is an essential part of a comprehensive assessment. Validation is confirming or verifying and opening the door to gathering more assessment data as it clarifies vague or unclear data. The process of checking and verifying the collected information is called data validation. The primary purpose of data validation is to ensure data is as free from error, bias, and misinterpretation as possible.
Nursing assessment guides are generally based on holistic models rather than medical...
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population attributable fraction.

BMJ (Clinical research ed.)·2018
Same author

Reporting guidelines for oncology research: helping to maximise the impact of your research.

British journal of cancer·2018
Same author

Updating standards for reporting diagnostic accuracy: the development of STARD 2015.

Research integrity and peer review·2018
Same author

Do declarative titles affect readers' perceptions of research findings? A randomized trial.

Research integrity and peer review·2018
Same author

Choosing important health outcomes for comparative effectiveness research: An updated systematic review and involvement of low and middle income countries.

PloS one·2018
Same author

The INTERGROWTH-21<sup>st</sup> fetal growth standards: toward the global integration of pregnancy and pediatric care.

American journal of obstetrics and gynecology·2018

Related Experiment Video

Updated: May 13, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

External validation of a Cox prognostic model: principles and methods.

Patrick Royston1, Douglas G Altman

  • 1Hub for Trials Methodology Research, MRC Clinical Trials Unit and University College London, Aviation House 125, Kingsway Country, London WC2B 6NH, UK. pr@ctu.mrc.ac.uk

BMC Medical Research Methodology
|March 19, 2013
PubMed
Summary

External validation of Cox models is crucial for clinical practice. This study presents methods for validating Cox models using varying levels of published information, aiding researchers in assessing model performance.

More Related Videos

Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Related Experiment Videos

Last Updated: May 13, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

Area of Science:

  • Biostatistics
  • Clinical Epidemiology
  • Prognostic Modeling

Background:

  • External validation is essential for prognostic models to ensure clinical utility.
  • External validation of Cox models is less explored than for logistic regression models.
  • Satisfactory discrimination and calibration are key metrics for successful model validation.

Purpose of the Study:

  • To describe statistical approaches for the external validation of published Cox models.
  • To address the challenges in validating Cox models due to unspecified baseline functions.
  • To provide a toolkit for researchers conducting external validation of Cox models.

Main Methods:

  • Methods are described based on the level of published information: prognostic index only, prognostic index with Kaplan-Meier curves, and inclusion of the baseline survival curve.
  • A method for approximating the baseline survival function is proposed for assessing calibration.
  • The approaches were applied to two primary breast cancer datasets, one as derivation and one as validation sample.

Main Results:

  • The study demonstrates the application of validation methods to primary breast cancer datasets.
  • Results for discrimination and calibration are presented.
  • Plots of survival probabilities are provided to aid in model evaluation.

Conclusions:

  • The proposed validation methods are applicable to diverse prognostic studies.
  • The methods offer a practical toolkit for the external validation of Cox models.
  • Successful validation ensures the reliable performance of prognostic models in new patient populations.